BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoon KT, Liu H, Lee SS. Cirrhotic Cardiomyopathy. Curr Gastroenterol Rep 2020;22:45. [PMID: 32651721 DOI: 10.1007/s11894-020-00783-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Abid NU, Mani AR. The mechanistic and prognostic implications of heart rate variability analysis in patients with cirrhosis. Physiol Rep 2022;10:e15261. [PMID: 35439350 DOI: 10.14814/phy2.15261] [Reference Citation Analysis]
2 Liu H, Yoon KT, Zhang J, Lee SS. Advances in cirrhotic cardiomyopathy. Curr Opin Gastroenterol 2021;37:187-93. [PMID: 33756518 DOI: 10.1097/MOG.0000000000000733] [Reference Citation Analysis]
3 Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.021] [Reference Citation Analysis]
4 Kaur H, Premkumar M. Diagnosis and Management of Cirrhotic Cardiomyopathy. Journal of Clinical and Experimental Hepatology 2022;12:186-99. [DOI: 10.1016/j.jceh.2021.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
6 Sturm L, Reincke M, Bettinger D. [Current pathophysiological concepts of acute decompensation in patients with liver cirrhosis and prognostic scores in different stages of disease]. Dtsch Med Wochenschr 2022;147:662-8. [PMID: 35636416 DOI: 10.1055/a-1671-9114] [Reference Citation Analysis]
7 Ma L, Liu X, Wu Q, Hu X, Liu H, Zhang J, Lee SS. Role of Anti-Beta-1-Adrenergic Receptor Antibodies in Cardiac Dysfunction in Patients with Cirrhotic Cardiomyopathy. J Cardiovasc Transl Res 2021. [PMID: 34417673 DOI: 10.1007/s12265-021-10161-5] [Reference Citation Analysis]
8 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bodys-Pełka A, Kusztal M, Raszeja-Wyszomirska J, Główczyńska R, Grabowski M. What's New in Cirrhotic Cardiomyopathy?-Review Article. J Pers Med 2021;11:1285. [PMID: 34945757 DOI: 10.3390/jpm11121285] [Reference Citation Analysis]
10 Adachi T, Takeuchi Y, Takaki A, Oyama A, Wada N, Onishi H, Shiraha H, Okada H. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. Int J Mol Sci 2021;22:5582. [PMID: 34070416 DOI: 10.3390/ijms22115582] [Reference Citation Analysis]
11 Kasper P, Steffen HM, Michels G. [Cirrhotic cardiomyopathy]. Dtsch Med Wochenschr 2021;146:1070-6. [PMID: 34416775 DOI: 10.1055/a-1321-9523] [Reference Citation Analysis]
12 Belcher JM, Parada XV, Simonetto DA, Juncos LA, Karakala N, Wadei HM, Sharma P, Regner KR, Nadim MK, Garcia-Tsao G, Velez JCQ, Parikh SM, Chung RT, Allegretti AS; HRS-HARMONY study investigators. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. Am J Kidney Dis 2021:S0272-6386(21)00890-8. [PMID: 34606933 DOI: 10.1053/j.ajkd.2021.08.016] [Reference Citation Analysis]